Drugs / PCV13
PCV13
Trials 23
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00566098 | Nov 2007 → Jun 2014 | plasma cell myeloma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03069703 | Feb 2018 → Nov 2020 | pneumococcal infection | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT03384589 | Aug 2018 → Mar 2023 | idiopathic severe pneumococcemia, pneumococcal infection | University of British Columbia | Completed | No outcome recorded |
| Phase 2/3 | NCT03098628 | Mar 2017 → Jun 2020 | — | Murdoch Childrens Research Institute | Completed | Mixed |
| Phase 2/3 | NCT01953510 | Sep 2013 → Jan 2016 | — | Murdoch Childrens Research Institute | Completed | Mixed |
| Phase 33 trials · 1 met primary | ||||||
| Phase 3 | NCT02943902 | Jan 2017 → Feb 2019 | meningitis, pneumonia | University of Witwatersrand, South Africa | Completed | Met primary |
| Phase 3 | NCT03205371 | Nov 2016 → Jul 2018 | meningococcal meningitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 3 | NCT00373958 | Sep 2006 → Jun 2008 | — | Pfizer | Completed | No outcome recorded |
| Phase 413 trials · 1 met primary · 2 missed | ||||||
| Phase 4 | NCT06210737 | Sep 2019 → Nov 2022 | pneumonia | Beijing Minhai Biotechnology Co., Ltd | Completed | No outcome recorded |
| Phase 4 | NCT03489018 | Mar 2019 → Sep 2022 | pneumococcal infection | London School of Hygiene and Tropical Medicine | Completed | Mixed |
| Phase 4 | NCT05316831 | Jan 2019 → Jun 2021 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Region Örebro County | Completed | No outcome recorded |
| Phase 4 | NCT03530124 | Jul 2018 → Nov 2021 | infantile apnea | Duke University | Completed | Missed primary |
| Phase 4 | NCT03619252 | Jul 2018 → Jan 2021 | bacterial pneumonia, neutropenia, plasma cell myeloma, pneumococcal infection | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | Completed | Missed primary |
| Phase 4 | NCT02637583 | Oct 2017 → Nov 2022 | pneumococcal infection | Jena University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03260790 | Oct 2017 → Dec 2020 | asthma | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT07154537 | Mar 2016 → Apr 2024 overdue | plasma cell myeloma | National Taiwan University Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03041051 | Dec 2015 → Mar 2017 | HIV infectious disease | Aghia Sophia Children's Hospital of Athens | Unknown | No outcome recorded |
| Phase 4 | NCT02492438 | Feb 2013 → Feb 2014 | chronic renal failure syndrome | AZ Sint-Jan AV | Completed | No outcome recorded |
| Phase 4 | NCT01846923 | Oct 2010 → Feb 2012 | beta-thalassemia major | Aghia Sophia Children's Hospital of Athens | Unknown | No outcome recorded |
| Phase 4 | NCT01095471 | Apr → Dec 2010 | pneumococcal infection | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT00744263 | Sep 2008 → Oct 2013 | streptococcal pneumonia | Pfizer | Completed | Met primary |
| Phase not applicable2 trials | ||||||
| — | NCT02012309 | Aug 2014 → Jun 2021 | HIV infectious disease, pneumococcal infection | University of Colorado, Denver | Unknown | No outcome recorded |
| — | NCT01852591 | Feb 2013 → Feb 2015 | plasma cell myeloma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 1 | NCT04525599 Comparator | Sep 2020 → Apr 2022 | pneumococcal infection | Affinivax, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03803202 Comparator | Jan 2019 → Sep 2020 | bacterial pneumonia, pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT03512288 Comparator | Apr 2018 → Feb 2020 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01282216 Comparator | Apr 2011 → Jan 2016 | cancer-related condition | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT05934890 Comparator | Nov 2023 → Mar 2025 overdue | pneumococcal infection | Walvax Biotechnology Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04384107 Comparator | Jul 2020 → Dec 2021 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | Mixed |
| Phase 4 | NCT04974294 Comparator | Jul 2021 → Jul 2023 | streptococcal pneumonia | Liverpool School of Tropical Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT03165981 Background | Aug 2017 → Jan 2018 | — | Duke University | Completed | Missed primary |
| Phase 4 | NCT03552445 Comparator | Nov 2013 → Apr 2016 | diphtheria, pneumococcal infection, tetanus | Korea University Guro Hospital | Completed | No outcome recorded |
Press releases naming this drug 7 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 39 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCV-13 | “A 20-valent PCV (PCV20) has been developed to add coverage for 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) to those in the existing 13-valent PCV (PCV13).” PMID 34525007 ↗ Oct 202132“13-Valent pneumococcal conjugate vaccine (PCV13) (PCV7 serotypes plus 1, 3, 5, 6A, 7F, and 19A) was designed to provide broader pneumococcal disease coverage.” PMID 20732948 ↗ Aug 2010 “the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) against first episodes of vaccine-type community-acquired pneumonia” PMID 29017280 ↗ Sep 2017 “a 0+1 schedule of PCV13 at 12 months of age (Group W)” NCT03098628 ↗ “13-valent (PCV-13) pneumococcal conjugate vaccine” PMID 24618837 ↗ Mar 2014 |
| Known as | 13-valent PCV | “A 20-valent PCV (PCV20) has been developed to add coverage for 7 additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) to those in the existing 13-valent PCV (PCV13).” PMID 34525007 ↗ Oct 2021 |
| Known as | 13-valent pneumococcal conjugate vaccine | “the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) against first episodes of vaccine-type community-acquired pneumonia” PMID 29017280 ↗ Sep 20173“a 13-valent pneumococcal conjugate vaccine (PCV13) induces robust early immune responses in such patients” PMID 30683996 ↗ Jan 2019 “the 13-valent pneumococcal conjugate vaccine (PCV13) has sufficient immunogenicity in children” PMID 39217777 ↗ Aug 2024 “13-valent pneumococcal conjugate vaccine (PCV13)” PMID 29722823 ↗ Jun 2018 |
| Known as | 13vPnC | “The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal vaccine (13vPnC) compare to the 7-valent pneumococcal...” NCT00373958 ↗ |
| Known as | pneumococcal conjugated vaccine 13 (PCV13) | “pneumococcal conjugated vaccine 13 (PCV13)” NCT07154537 ↗ |
| Known as | Prevenar 13 | “Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A,...” NCT03619252 ↗ |
| Known as | Prevnar 13 | “Vaccination with pneumococcal conjugate vaccine - PCV13 (Prevnar 13/Prevenar 13, Pfizer Inc) containing saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A,...” NCT03619252 ↗ |
| Modality | Vaccine | “A 13-valent pneumococcal conjugate vaccine (PCV13) has been licensed in >100 countries to broaden coverage against pneumococcal disease.” PMID 23104129 ↗ Apr 2013 |
| Route | Intramuscular | “0.5 mL, single intra-muscular injection” NCT00744263 ↗ |